Skoči na glavni sadržaj

Rad Hrvatske akademije znanosti i umjetnosti. Medicinske znanosti, Vol. 563 No. 66-67, 2024.

Studija slučaja

Glucagon-like peptide-1 (GLP-1) receptor agonist as cardio- and nephroprotection in a patient with diabetic kidney disease and proximal myotonic myopathy type 2 (PROMM MD2)

Danilo Radunović orcid id orcid.org/0000-0001-8417-9199 ; Clinic for Nephrology, Clinical Center of Montenegro, Podgorica, Montenegro *
Vladimir Prelević ; Clinic for Nephrology, Clinical Center of Montenegro, Podgorica, Montenegro
Filip Tomović orcid id orcid.org/0009-0005-9376-9971 ; Clinic for Nephrology, Clinical Center of Montenegro, Podgorica, Montenegro
Marija Domislović ; Divison of Nephrology, Arterial Hypertension, Dialysis and Transplantation; University Hospital Center Zagreb, Zagreb, Croatia
Bojan Jelaković ; Clinical Hospital Center Zagreb, Nephrology, Arterial Hypertension, Dialysis and Transplantation Department, Zagreb, Croatia

* Dopisni autor.

Puni tekst: engleski pdf 271 Kb

str. 112-115

preuzimanja: 57

citiraj

Sažetak

We present a 42-year old male patient, with diabetic kidney disease, progressing proximal myotonic myopathy type 2 (PROMM MD2), metabolic syndrome and several comorbidities. Due to PROMM MD2, the patient had a mixed restrictive-obstructive disorder of pulmonary ventilation, a large ventral hernia, along with weakening of the anterior abdominal wall musculature, relaxation of the paravertebral musculature, discopathy and radiculopathy of the lumbosacral spine. The patient had an extremely high cardiometabolic risk for cardiovascular and cerebrovascular accidents. The patient was treated with a glucagon-like peptide-1 (GLP-1) receptor agonist for cardio- and nephroprotection, along with treatment of all associated conditions, specific diet and adapted physical therapy. In the subsequent follow-ups at 3 and 6 months after the treatment start, an improvement in several components of the metabolic syndrome and renal function was noted. The patient had a significant reduction in body weight, better glucoregulation, a significant reduction of proteinuria, maintained renal function, and better lipid profile. The overall cardiovascular risk was significantly reduced. GLP 1 receptor agonists could be used as effective cardiorenal protection in patients with progressive neuromuscular diseases.

Ključne riječi

neuromuscular diseases; metabolic syndrome; GLP-1R agonist

Hrčak ID:

318624

URI

https://hrcak.srce.hr/318624

Datum izdavanja:

25.6.2024.

Posjeta: 122 *